Cost-benefit analysis of pharmaceutical treatments of infertility using willingness to pay approach

Introdution: Due to the high prevalence of infertility in Iran and the high costs of infertility treatments, analysis the economic issues of this scope seems important. The aim of this study was to present the scientific evidence of the community valuation for infertility pharmaceutical treatments a...

Full description

Bibliographic Details
Main Authors: Ali Darvishi, Reza Goudarzi, Victoria Habib Zadeh, Mohsen Barouni
Format: Article
Language:fas
Published: Shahid Sadoughi University of Medical Sciences 2018-06-01
Series:Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd
Subjects:
Online Access:http://jssu.ssu.ac.ir/browse.php?a_code=A-10-2553-1&slc_lang=en&sid=1
_version_ 1811261677866319872
author Ali Darvishi
Reza Goudarzi
Victoria Habib Zadeh
Mohsen Barouni
author_facet Ali Darvishi
Reza Goudarzi
Victoria Habib Zadeh
Mohsen Barouni
author_sort Ali Darvishi
collection DOAJ
description Introdution: Due to the high prevalence of infertility in Iran and the high costs of infertility treatments, analysis the economic issues of this scope seems important. The aim of this study was to present the scientific evidence of the community valuation for infertility pharmaceutical treatments and precise costing of these treatments using economic analysis. Methods: This study was a cross-sectional study of cost-benefit one of the economic evaluation of the health interventions studies. The per capita cost of one cycle of infertility pharmaceutical treatments was calculated based on the treatment protocols and prescriptions of physicians. Measuring the willingness to pay people was done using a contingent valuation method (CVM) using a researcher-made questionnaire in Kerman. Results: Per capita cost per cycle of infertility pharmaceutical treatments was estimated at 6689640 Rls. The willingness to pay for these treatments was also 13198125 Rls per treatment cycle. Based on the cost and outcome, the calculated net present value (NPV) and the benefit cost ratio (BCR) were 6508485 Rls and 1.97, respectively. Conclusion: According to the results of the study, the valuation of individuals for infertility pharmaceutical treatments is about twice the cost of one cycle of these treatments, which suggests that investment for this level of treatments has a positive net benefit. Therefore, it is required that policy-makers pay more attention to the issue of scientific financing of infertility in the current period that we require population growth in Iran.
first_indexed 2024-04-12T19:10:01Z
format Article
id doaj.art-38162d639fd1485bb9b1662e462067bc
institution Directory Open Access Journal
issn 2228-5741
2228-5733
language fas
last_indexed 2024-04-12T19:10:01Z
publishDate 2018-06-01
publisher Shahid Sadoughi University of Medical Sciences
record_format Article
series Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd
spelling doaj.art-38162d639fd1485bb9b1662e462067bc2022-12-22T03:19:54ZfasShahid Sadoughi University of Medical SciencesMajallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd2228-57412228-57332018-06-01263245256Cost-benefit analysis of pharmaceutical treatments of infertility using willingness to pay approachAli Darvishi0Reza Goudarzi1Victoria Habib Zadeh2Mohsen Barouni3 School of Public Health, Tehran University of Medical Sciences, Tehran Kerman University of Medical Sciences, Kerman Kerman University of Medical Sciences, Kerman Kerman University of Medical Sciences, Kerman Introdution: Due to the high prevalence of infertility in Iran and the high costs of infertility treatments, analysis the economic issues of this scope seems important. The aim of this study was to present the scientific evidence of the community valuation for infertility pharmaceutical treatments and precise costing of these treatments using economic analysis. Methods: This study was a cross-sectional study of cost-benefit one of the economic evaluation of the health interventions studies. The per capita cost of one cycle of infertility pharmaceutical treatments was calculated based on the treatment protocols and prescriptions of physicians. Measuring the willingness to pay people was done using a contingent valuation method (CVM) using a researcher-made questionnaire in Kerman. Results: Per capita cost per cycle of infertility pharmaceutical treatments was estimated at 6689640 Rls. The willingness to pay for these treatments was also 13198125 Rls per treatment cycle. Based on the cost and outcome, the calculated net present value (NPV) and the benefit cost ratio (BCR) were 6508485 Rls and 1.97, respectively. Conclusion: According to the results of the study, the valuation of individuals for infertility pharmaceutical treatments is about twice the cost of one cycle of these treatments, which suggests that investment for this level of treatments has a positive net benefit. Therefore, it is required that policy-makers pay more attention to the issue of scientific financing of infertility in the current period that we require population growth in Iran.http://jssu.ssu.ac.ir/browse.php?a_code=A-10-2553-1&slc_lang=en&sid=1Cost benefit analysis Infertility Pharmaceutical treatments Willingness to pay Economic evaluation
spellingShingle Ali Darvishi
Reza Goudarzi
Victoria Habib Zadeh
Mohsen Barouni
Cost-benefit analysis of pharmaceutical treatments of infertility using willingness to pay approach
Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd
Cost benefit analysis
Infertility
Pharmaceutical treatments
Willingness to pay
Economic evaluation
title Cost-benefit analysis of pharmaceutical treatments of infertility using willingness to pay approach
title_full Cost-benefit analysis of pharmaceutical treatments of infertility using willingness to pay approach
title_fullStr Cost-benefit analysis of pharmaceutical treatments of infertility using willingness to pay approach
title_full_unstemmed Cost-benefit analysis of pharmaceutical treatments of infertility using willingness to pay approach
title_short Cost-benefit analysis of pharmaceutical treatments of infertility using willingness to pay approach
title_sort cost benefit analysis of pharmaceutical treatments of infertility using willingness to pay approach
topic Cost benefit analysis
Infertility
Pharmaceutical treatments
Willingness to pay
Economic evaluation
url http://jssu.ssu.ac.ir/browse.php?a_code=A-10-2553-1&slc_lang=en&sid=1
work_keys_str_mv AT alidarvishi costbenefitanalysisofpharmaceuticaltreatmentsofinfertilityusingwillingnesstopayapproach
AT rezagoudarzi costbenefitanalysisofpharmaceuticaltreatmentsofinfertilityusingwillingnesstopayapproach
AT victoriahabibzadeh costbenefitanalysisofpharmaceuticaltreatmentsofinfertilityusingwillingnesstopayapproach
AT mohsenbarouni costbenefitanalysisofpharmaceuticaltreatmentsofinfertilityusingwillingnesstopayapproach